Kamada is focused on plasma-derived protein therapeutics for orphan indications, with an existing marketed product portfolio and a late-stage product pipeline. Kamada uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce certain proteins in a highly-purified, liquid form with known and newly-discovered therapeutic roles given its immunomodulatory, anti-inflammatory, tissue-protective and antimicrobial properties. Kamada’s flagship product, Glassia, is the first liquid and ready-to-use, plasma derived protein product approved by the US FDA for the treatment of emphysema in patients with a genetic hereditary deficiency.